keyword
MENU ▼
Read by QxMD icon Read
search

Merkel cell carcinoma

keyword
https://www.readbyqxmd.com/read/29148079/insm1-a-novel-nuclear-marker-in-merkel-cell-carcinoma-cutaneous-neuroendocrine-carcinoma
#1
Patrick S Rush, Jason N Rosenbaum, Madhuchhanda Roy, Rebecca M Baus, Daniel D Bennett, Ricardo V Lloyd
Merkel cell carcinoma (MCC) is a rare, clinically aggressive, cutaneous neuroendocrine (NE) neoplasm. As a tumor with small, round, blue cells, the histologic differential diagnosis for MCC can include melanoma, metastatic small cell carcinoma (SCC), nodular hematopoietic tumors, basal cell carcinoma (BCC), atypical variants of squamous carcinoma, and the uncommon occurrence of primary cutaneous Ewing sarcoma. In cases with atypical histology or without the classic immunophenotype the diagnosis can be challenging...
November 17, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29145324/a-rare-case-of-merkel-cell-carcinoma-presenting-as-a-giant-intra-thoracic-mass-a-case-report-and-review-of-the-literature
#2
Feng-Wei Kong, Miao Zhang, Heng Wang, Cun-Tao Lu, Wen-Bin Wu, Yuan-Yuan Liu
RATIONALE: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine-derived cutaneous cancer. Ectopic or single metastatic MCC located in thorax is extremely rare; meanwhile, its definite management has not been elucidated yet. PATIENT CONCERNS: A 64-year-old female patient with a giant mass located in her left thorax was presented for stuffy pain of left chest for 6 months and fever for half a month. She underwent radical resection of vulvar MCC 10 years ago...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29142746/interaction-between-merkel-cell-carcinoma-and-the-immune-system-pathogenetic-and-therapeutic-implications
#3
Irene Zanetti, Ilaria Coati, Mauro Alaibac
Merkel cell carcinoma (MCC) is a rare, aggressive primary cutaneous neuroendocrine carcinoma. It usually appears on the face and neck of elderly Caucasian people as a flesh-colored, erythematous or violaceous dome-shaped, non-tender nodule with a smooth surface. In immunocompromised patients with T-cell dysfunction, such as patients with acquired immunodeficiency syndrome (AIDS) or solid organ transplant recipients, the incidence of this disease is markedly increased. This suggests a link between the development of MCC and the immune system...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29123950/immune-evasion-mechanisms-and-immune-checkpoint-inhibition-in-advanced-merkel-cell-carcinoma
#4
REVIEW
Dirk Schadendorf, Paul Nghiem, Shailender Bhatia, Axel Hauschild, Philippe Saiag, Lisa Mahnke, Subramanian Hariharan, Howard L Kaufman
Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. However, inhibitory immune molecules, including programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1), within the MCC tumor microenvironment aid in tumor evasion of T-cell-mediated clearance...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29108353/evaluation-of-real-world-treatment-outcomes-in-patients-with-distant-metastatic-merkel-cell-carcinoma-following-second-line-chemotherapy-in-europe
#5
Jürgen C Becker, Eva Lorenz, Selma Ugurel, Thomas K Eigentler, Felix Kiecker, Claudia Pföhler, Ivonne Kellner, Friedegund Meier, Katharina Kähler, Peter Mohr, Carola Berking, Gabriele Haas, Christoph Helwig, Dina Oksen, Dirk Schadendorf, Lisa Mahnke, Murtuza Bharmal
Background and aims: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer; few treatments exist for patients with advanced disease. Once tumors metastasize to distant sites, patients generally receive chemotherapy, but response duration and progression-free survival (PFS) are typically short. Few studies have assessed the efficacy of second-line chemotherapy for metastatic MCC. Here, we studied outcomes in patients who received ≥ 2 lines of chemotherapy for metastatic MCC. Materials and methods: Patients in an MCC-specific registry diagnosed with stage IV MCC between November 1, 2004, and September 15, 2015, and treated with second-line or later chemotherapy were analyzed retrospectively...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103968/anti-pd-l1-tgf%C3%AE-r2-m7824-fusion-protein-induces-immunogenic-modulation-of-human-urothelial-carcinoma-cell-lines-rendering-them-more-susceptible-to-immune-mediated-recognition-and-lysis
#6
Italia Grenga, Renee N Donahue, Morgan L Gargulak, Lauren M Lepone, Mario Roselli, Marijo Bilusic, Jeffrey Schlom
BACKGROUND: Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ "trap." Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis...
November 2, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29103738/a-pilot-study-of-merkel-cell-polyomavirus-in-squamous-cell-carcinoma-of-the-tongue
#7
Mickie Hamiter, Ameya Asarkar, Donna Rogers, Tara Moore-Medlin, Gloria McClure, Xiaohui Ma, John Vanchiere, Cherie-Ann O Nathan
No abstract text is available yet for this article.
November 2017: Oral Oncology
https://www.readbyqxmd.com/read/29102486/merkel-cell-carcinoma-current-united-states-incidence-and-projected-increases-based-on-changing-demographics
#8
Kelly G Paulson, Song Youn Park, Natalie A Vandeven, Kristina Lachance, Hannah Thomas, Aude G Chapuis, Kelly L Harms, John A Thompson, Shailender Bhatia, Andreas Stang, Paul Nghiem
BACKGROUND: Merkel cell carcinoma (MCC) incidence rates are rising and strongly age-associated, relevant for an aging population. OBJECTIVE: Determine MCC incidence in the United States and project incident cases through the year 2025. METHODS: Registry data were obtained from the SEER-18 database, containing 6,600 MCC cases. Age and sex-adjusted projections were generated utilizing US census data. RESULTS: Between 2000-2013, there was a 95% increase in the number of reported MCC cases, compared to 57% for melanoma and 15% for all 'solid' cancers...
November 1, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29093086/merkel-cell-polyomavirus-small-t-antigen-drives-cell-motility-via-rho-gtpase-induced-filopodia-formation
#9
Gabrielė Stakaitytė, Nnenna Nwogu, Samuel J Dobson, Laura M Knight, Christopher W Wasson, Francisco J Salguero, David J Blackbourn, G Eric Blair, Jamel Mankouri, Andrew Macdonald, Adrian Whitehouse
Cell motility and migration is a complex, multi-step, and multi-component process, intrinsic to progression and metastasis. Motility is dependent on the activity of integrin receptors and Rho-family GTPases resulting in the remodelling of the actin cytoskeleton and formation of various motile actin-based protrusions. Merkel cell carcinoma (MCC) is an aggressive skin cancer with a high likelihood of recurrence and metastasis. Merkel cell polyomavirus (MCPyV) is associated with the majority of MCC cases, and MCPyV-induced tumourigenesis largely depends on the expression of the small tumour antigen (ST)...
November 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29079179/genetic-profiles-of-different-subsets-of-merkel-cell-carcinoma-show-links-between-combined-and-pure-mcpyv-negative-tumors
#10
Michael D Carter, Dan Gaston, Weei-Yuarn Huang, Wenda L Greer, Sylvia Pasternak, Thai Yen Ly, Noreen M Walsh
Tumorigenesis in Merkel cell carcinoma (MCC) is driven by (i) clonal integration of the Merkel cell polyomavirus (MCPyV) in neoplastic cells and/or (ii) genetic damage by ultraviolet (UV) light. A higher mutational burden, a UV-mutational signature, and many mutations in the TP53 and RB1 genes characterize the virus-negative subset. MCPyV-negative MCCs include combined (often squamous and neuroendocrine) and pure (neuroendocrine) tumors. Because a combined morphology could elude detection microscopically, we sought a genetic link between combined and pure virus-negative tumors...
October 24, 2017: Human Pathology
https://www.readbyqxmd.com/read/29072946/histologic-mimics-of-basal-cell-carcinoma
#11
REVIEW
Lauren M Stanoszek, Grace Y Wang, Paul W Harms
CONTEXT: - Basal cell carcinoma (BCC) is the most common human malignant neoplasm and is a frequently encountered diagnosis in dermatopathology. Although BCC may be locally destructive, it rarely metastasizes. Many diagnostic entities display morphologic and immunophenotypic overlap with BCC, including nonneoplastic processes, such as follicular induction over dermatofibroma; benign follicular tumors, such as trichoblastoma, trichoepithelioma, or basaloid follicular hamartoma; and malignant tumors, such as sebaceous carcinoma or Merkel cell carcinoma...
November 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29072302/merkel-cell-carcinoma
#12
REVIEW
Jürgen C Becker, Andreas Stang, James A DeCaprio, Lorenzo Cerroni, Celeste Lebbé, Michael Veness, Paul Nghiem
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics...
October 26, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/29072252/merkel-cell-carcinoma
#13
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
October 26, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/29066044/iatrogenic-solid-tumors-following-immunosuppressive-therapy
#14
REVIEW
Kossivi Dantey, Liron Pantanowitz
Immunosuppression induced by chronic medication, such as occurs post-transplantation, may increase a patient's risk of developing solid tumors. These are often rare tumors characterized by odd presentations. This review focuses on commonly encountered iatrogenic, non-hematopoietic solid tumors following immunotherapy and provides a practical approach to their diagnosis. All of the malignancies covered in this review are viral-induced. They include human papillomavirus (HPV)-associated carcinomas, Epstein-Barr virus (EBV)-associated tumors, Merkel cell polyomavirus (MCPyV)-related Merkel cell carcinoma, and Human Herpesvirus 8 (HHV8)-related Kaposi sarcoma...
September 20, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29055440/merkel-cell-carcinoma-with-fingolimod-treatment-for-multiple-sclerosis-a-case-report
#15
Kedar R Mahajan, Jennifer S Ko, Michael T Tetzlaff, Courtney W Hudgens, Steven D Billings, Jeffrey A Cohen
Neoplasms and reactivation of latent viruses have been observed in individuals taking fingolimod. Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer, is associated with immunosuppression and can be triggered by the oncogenic Merkel cell polyoma virus (MCPyV). We report a case of a 61-year-old man with multiple sclerosis who developed MCPyV-positive MCC 4 years after starting fingolimod. This is the second report of MCC associated with MCPyV in an individual on fingolimod.
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29052284/cytological-diagnosis-of-a-rare-case-of-primary-merkel-cell-carcinoma-of-the-parotid-gland
#16
T Bizzarro, R Buda, M Ricci, L Bernardi
No abstract text is available yet for this article.
October 20, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/29052131/merkel-cell-polyomavirus-a-new-dna-virus-associated-with-human-cancer
#17
Margo MacDonald, Jianxin You
Merkel cell polyomavirus (MCPyV or MCV) is a novel human polyomavirus that has been discovered in Merkel cell carcinoma (MCC), a highly aggressive skin cancer. MCPyV infection is widespread in the general population. MCPyV-associated MCC is one of the most aggressive skin cancers, killing more patients than other well-known cancers such as cutaneous T-cell lymphoma and chronic myelogenous leukemia (CML). Currently, however, there is no effective drug for curing this cancer. The incidence of MCC has tripled over the past two decades...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29040209/inherited-and-acquired-clinical-phenotypes-associated-with-neuroendocrine-tumors
#18
Rory E Nicholaides, M Teresa de la Morena
PURPOSE OF REVIEW: Overview of neuroendocrine neoplasms in the context of their associations with primary and secondary immunodeficiency states. RECENT FINDINGS: Malignancies of neuroendocrine origin are well known to be associated with hereditary syndromes, including multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome, neurofibromatosis type 1, and tuberous sclerosis. This review includes the X-linked form of hyper-IgM syndrome (XHIGM), due to mutations in the CD40Ligand gene (CD40LG), as an additional inherited disorder with susceptibility to such malignancies, and discusses neuroendocrine tumors (NETs) arising in other immunocompromised states...
December 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29034299/a-case-of-merkel-cell-carcinoma-development-under-treatment-with-a-janus-kinase-inhibitor
#19
Yuta Koike, Naoya Murayama, Yutaka Kuwatsuka, Atsushi Utani
No abstract text is available yet for this article.
November 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/29033592/is-this-the-end-of-cytotoxic-chemotherapy-in-merkel-cell-carcinoma
#20
REVIEW
Guilherme Rabinowits
Although cytotoxic chemotherapy has been used often in the management of Merkel cell carcinoma (MCC), its benefit remains uncertain. Despite being considered a chemosensitive disease, the duration of response is generally short, and the survival benefit is unclear. With the recent FDA approval of the anti-programmed cell death ligand 1 (PD-L1) antibody avelumab for patients with advanced MCC and the limited and controversial data on chemotherapy, it is important to put in perspective whether conventional chemotherapy should remain an option for these patients...
2017: OncoTargets and Therapy
keyword
keyword
5085
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"